Wednesday, July 29, 2015 7:26:30 PM
By Nick Kostov
PARIS--Sanofi SA on Wednesday announced a new corporate structure that the French pharmaceuticals company said would make it more efficient and optimise growth, as the company's new chief executive puts his stamp on the business.
Sanofi, which in February named Olivier Brandicourt as its new chief executive, said it is organising itself into five global business units, with the structure set to be implemented in January 2016. Sanofi didn't say if the move would lead to any staff cuts or how much would be saved.
"The new organization simplifies and focuses Sanofi to optimize growth," said Mr. Brandicourt.
The company will now be divided along the lines of general medicines and emerging markets, specialty care, diabetes and cardiovascular, Sanofi Pasteur and Merial. Sanofi had listed seven businesses in its 2014 earnings.
Sanofi named Mr. Brandicourt CEO in February, appointing a pharmaceutical veteran to lead one of the world's largest drug and vaccine makers as it faces stiff competition and prepares to launch crucial new products.
Mr. Brandicourt's appointment ended months of speculation over who would take the reins at the French drug maker after the abrupt ouster of Christopher Viehbacher in October.
Sanofi said it aims to launch six new medicines in 2015 and approximately one every six months between 2016 and 2018.
Recent SNY News
- Paramount’s Shares Surge Following Sony and Apollo’s Joint Bid; ISS Backs Berkshire Hathaway Director Re-election, and More • IH Market News • 04/19/2024 11:31:22 AM
- Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)). • Edgar (US Regulatory) • 02/23/2024 07:02:56 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/23/2024 04:15:26 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/15/2024 05:09:49 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 08:57:49 PM
- Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE) • GlobeNewswire Inc. • 01/25/2024 07:29:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/23/2024 12:23:49 PM
- Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- Update • Dow Jones News • 01/23/2024 11:05:00 AM
- Wall Street Highlights: Vroom Shuts Down Online Car Sales, Ericsson Warns of Decline Outside China, and More • IH Market News • 01/23/2024 10:40:18 AM
- Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B • PR Newswire (US) • 01/23/2024 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/17/2024 06:49:56 PM
- Sanofi Names Brian Foard Head of Specialty-Care Unit • Dow Jones News • 01/09/2024 07:14:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/27/2023 04:18:58 PM
- Sanofi Ends Drug Program After Late-Stage Trial in Lung Cancer Fails • Dow Jones News • 12/21/2023 07:25:00 AM
- Innate Pharma Shares Rise after Sanofi Exercises Licensing Option • Dow Jones News • 12/19/2023 12:28:00 PM
- Hasbro Job Cuts, Oracle’s Stock Decline, Google’s Epic Antitrust Loss, and More • IH Market News • 12/12/2023 10:50:47 AM
- Sanofi Terminates Agreement with Maze Therapeutics Following FTC Opposition • Dow Jones News • 12/11/2023 10:18:00 PM
- Sanofi Sees Improvement in Trial Results of Cancer Drug Sarclisa • Dow Jones News • 12/11/2023 06:50:00 AM
- Sanofi Myeloma Drug Sarclisa Met Primary Goal in Late-Stage Trial • Dow Jones News • 12/07/2023 07:34:00 AM
- Sanofi Sees Annual Sales From New Pharma Assets Above $10.8 Billion by 2030 • Dow Jones News • 12/07/2023 07:20:00 AM
- Trending: Merck's Multiple Sclerosis Drug Misses Expectations in Late-Stage Trials • Dow Jones News • 12/06/2023 01:20:00 PM
- Merck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage Trials • Dow Jones News • 12/06/2023 10:14:00 AM
- Teva Closes Collaboration Deal With Sanofi on IBD Treatment • Dow Jones News • 11/30/2023 02:23:00 PM
- Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment • Business Wire • 11/30/2023 01:30:00 PM
- Trending: Sanofi's Notus Trial Meets Primary Endpoint • Dow Jones News • 11/27/2023 03:31:00 PM
FEATURED Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • Apr 22, 2024 8:49 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM